In 2015, the fastest growing segment in the electrophysiology and ablation market was diagnostic EP catheter devices. Over the forecast period, growth will be driven mostly by the conventional steerable catheter market, which is expected to increase at nearly double digit growth rates every year, partly due to its relatively low price compared to advanced catheters such as loop and mapping catheters. Over the forecast period, the electrophysiology and ablation device market will be driven by the aging population, rise in cardiac ablation procedures and adoption of advanced EP devices. For the relatively newer devices used in electrophysiology and ablation markets, continued education is critical to increase cardiologists confidence in these types of cardiac treatments.
The EP market is expected to experience growth across all product segments over the forecast period. The more recent products are expected to experience strong growth on a percentage basis but not on an absolute unit or market growth basis simply because newer devices take a while for physicians to adopt. Also, considering the severity of the procedures, it will take years of practice before a device can fully take off. Therefore, most of the devices sold for newer market segments will go towards training and clinical studies. Throughout the forecast period, there is expected to be a significant growth in demand for catheter-based ablation procedures due to an increase in public knowledge, technological improvements and an increase in the number of EP labs in rural areas.
Biosense Webster was the leading competitor in the EP lab system, ablation catheter and diagnostic EP catheter markets. The company has been able to maintain its dominant position in the market by offering a wide range of EP and ablation devices while utilizing their expansive distribution network to improve sales. The company retains its title as majority market leader in ablation with nearly 50% of the entire market. Other major competitors in the market include Angiodynamics, Biotronik, Boston Scientific, GE Healthcare, MicroPort, Siemens, Stereotaxis, St. Jude Medical and Topera. Certain companies, such as Boston Scientific and St. Jude Medical, also offer a wide range of EP and ablation products and sell them through large distribution networks.
This report also includes an analysis of other factors and trends that have positively and negatively impacted the market.
Electrophysiology and Cardiac Abalation Device Market Report Data Types Included
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2022, and Historical Data to 2012
- Market Drivers & Limiters for Each Device Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Related Press Releases from Top Competitors
Electrophysiology and Cardiac Abalation Device Companies Analyzed
In 2015, Biosense Webster led the total market for EP and cardiac ablation devices. This was due to their dominance in the lab system, diagnostic EP catheter and cardiac ablation catheter segments. St Jude Medical was the second leading competitor in the EP and cardiac ablation market. They were able to make considerable gains in the diagnostic EP catheter market at Biosense Webster’s expense after the Duo-Decapolar® EP catheter was recalled due to defects.
Other companies researched in this report include Medtronic, GE Healthcare, Siemens, Angiodynamics, Cameron Health, EGI, EsTech, Elmiko Medical, Lepu Medical, MicroPort and various others.